Asta Medica, Aktiengesellschaft

Zentaris Gmbh

Zentaris Ag

Michael Bernd

Bernhard Kutscher

Thomas Beckers

Thomas Reissmann

Peter Romeis

Jurgen Engel

Thomas Klenner

Horst Kessler

Ulf Niemeyer

Eckhard G&uuml;nther

Rainer Voegeli

Erich G Roedern

Heinz Grossmann

Maria Kick

Jurgen Arp

Manfred Lieflander

Patricia-Marie Charpentier

Peter-Paul Emig

The invention relates to peptides which contain N-methylated amino acid units and have improved water solubility. The invention also relates methods for treating a hormone-dependent tumor or a non-malignant indication that is treatable by LH-RH suppression, the method comprising administering to a patient in need of the treatment a therapeutically effective amount of a compound of the invention. Hormone-dependent cancers that can be treated with the methods of the invention include prostate cancer, breast cancer, ovarian cancer, endometrial cancer, and pancreatic cancer. Non-malignant indications which can be treated by the methods of the invention include benign prostate hyperplasia (BPH), endometriosis, acne, polycystic ovarian disease, dysmenorrhea, precocious puberty, and uterine fibroids and other leiomyomas.

Methods of treatment using novel LHRH antagonists having improved solubility properties

The invention relates to peptides which contain N-methylated amino acid units and have improved water solubility. Medicaments in which the peptides according to the invention are contained can be used for the treatment of hormone-dependent tumors and hormone-influenced non-malignant disorders.

LHRH antagonists having improved solubility properties

The invention relates to peptides which contain N-methylated amino acid units and have improved water solubility. Medicaments in which the peptides according to the invention are contained can be used for the treatment of hormone-dependent tumours and hormone-influenced non-malignant disorders.

Nova- and decapeptides in the preparation of a drug for the treatment of

New LH-RH antagonists are disclosed, in particular peptidomimetics and peptides modified in a side chain, their salts with pharmaceutically acceptable acids and a process for preparing these LH-RH antagonists and their salts. The disclosed peptides represent analogues of the luteinising hormone releasing hormone (LH-RH). The disclosed compounds have a high antagonistic power and are free of undesirable side effects, in particular edematogenic effects.

LH-RH antagonists having improved action

Long-chain, unbranched alkylamides of the general formula

Long-chain alkylamides of amino acids and peptides with

Use of 7-amino-L-glycero-L-gulo-2,6-anhydro-7-desoxy-heptonic acid and 2-benzoxycarbonylamino-0.sup.1 -methyl-2-desoxy-.beta.-glucopyranuronic acid, their derivatives and the enantiomorphous compounds for incorporation and for manufacture in pharmacologically active peptide hormones.

Use of D-glucopyranuronic acids and their derivatives for incorporation

Growing community of inventors

Frankfurt-am-Main, Germany

Michael Bernd